{"id":823657,"date":"2025-03-10T09:23:18","date_gmt":"2025-03-10T13:23:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/"},"modified":"2025-03-10T09:23:18","modified_gmt":"2025-03-10T13:23:18","slug":"mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","title":{"rendered":"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, March 10, 2025<\/span><\/span> \/PRNewswire\/ — Robbins Geller Rudman<\/span> & Dowd LLP<\/a><\/b> announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024<\/span> and February 24, 2025<\/span>, both dates inclusive (the “Class Period”), have until May 5, 2025<\/span> to seek appointment as lead plaintiff of the Maravai <\/i>class action lawsuit.\u00a0 Captioned Nelson v. Maravai LifeSciences Holdings, Inc.<\/i>, No. 25-cv-00499 (S.D. Cal.), the Maravai <\/i>class action lawsuit charges Maravai as well as certain of Maravai’s top executives with violations of the Securities Exchange Act of 1934.<\/p>\n

\n

\n
\n \"Robbins
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n If you suffered substantial losses and wish to serve as lead plaintiff of the Maravai <\/i>class action lawsuit, please provide your information here:<\/b>\n <\/p>\n

\n
\n https:\/\/www.rgrdlaw.com\/cases-maravai-lifesciences-holdings-inc-class-action-lawsuit-mrvi.html<\/a>
\n <\/b>\u00a0<\/p>\n

\n You can also contact attorneys J.C. Sanchez<\/a> or Jennifer N. Caringal<\/span><\/a> of Robbins Geller by calling 800\/449-4900 or via e-mail at info@rgrdlaw.com<\/a>.<\/b>\n <\/p>\n

\n CASE ALLEGATIONS<\/b>: Maravai is a provider of biologics to support clinical research.<\/p>\n

The Maravai <\/i>class action lawsuit alleges<\/span> that defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (i) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (ii) as a result, Maravai inaccurately recognized revenue on certain transactions during fiscal 2024; and (iii) Maravai’s goodwill was overstated.<\/p>\n

The Maravai<\/i> class action lawsuit further alleges<\/span> that on February 25, 2025<\/span>, Maravai revealed that it was postponing its fiscal 2024 earnings release and would delay filing its annual report, noting that Maravai required additional time to complete its year-end financial close for reasons related primarily to “its assessment of a potential non-cash impairment charge related to goodwill associated with its previous acquisition of Alphazyme LLC,” “an error identified during the close process with respect to revenue recognition associated with a single shipment identified in year-end audit procedures that resulted in approximately $3.9 million<\/span> in revenue being recorded in the final week of the second quarter of 2024 upon shipment when it should have been recorded in the first week of the third quarter of 2024 upon receipt by the customer,” and “the effectiveness of its disclosure controls and procedures and internal controls over financial reporting as of December 31, 2024<\/span>, and any remediation, including with respect to remediation of a material weakness in its internal controls over revenue recognition identified by management.” \u00a0On this news, the price of Maravai stock fell nearly 22%, according to the complaint.<\/p>\n

\n THE LEAD PLAINTIFF PROCESS<\/b>: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Maravai securities during the Class Period to seek appointment as lead plaintiff in the Maravai <\/i>class action lawsuit.\u00a0 A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. \u00a0A lead plaintiff acts on behalf of all other class members in directing the Maravai <\/i>class action lawsuit.\u00a0 The lead plaintiff can select a law firm of its choice to litigate the Maravai <\/i>class action lawsuit.\u00a0 An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Maravai <\/i>class action lawsuit.<\/p>\n

\n ABOUT ROBBINS GELLER<\/b>: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud<\/span> cases.\u00a0 Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors.\u00a0 We recovered $6.6 billion<\/span> for investors in securities-related class action cases \u2013 over $2.2 billion<\/span> more than any other law firm in the last four years.\u00a0 With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever \u2013 $7.2 billion<\/span> \u2013 in In re Enron Corp. Sec. Litig.<\/i>\u00a0 Please visit the following page for more information:<\/p>\n

\n
\n https:\/\/www.rgrdlaw.com\/services-litigation-securities-fraud<\/span>.html<\/a>
\n <\/b>\n <\/p>\n

Past results do not guarantee future outcomes.\u00a0<\/p>\n

Services may be performed by attorneys in any of our offices.\u00a0<\/p>\n

Contact:
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Robbins Geller Rudman & Dowd LLP
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 J.C. Sanchez, Jennifer N. Caringal<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 655 W. Broadway, Suite 1900, San Diego, CA<\/span> 92101
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 800-449-4900
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 info@rgrdlaw.com<\/a><\/b>\u00a0<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302396236.html<\/a><\/p>\n

SOURCE Robbins Geller Rudman & Dowd LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO , March 10, 2025 \/PRNewswire\/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), have until May 5, 2025 to seek appointment as lead plaintiff of the Maravai class action lawsuit.\u00a0 Captioned Nelson v. Maravai LifeSciences Holdings, Inc., No. 25-cv-00499 (S.D. Cal.), the Maravai class action lawsuit charges Maravai as well as certain of Maravai’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Maravai class action lawsuit, please provide your information here: https:\/\/www.rgrdlaw.com\/cases-maravai-lifesciences-holdings-inc-class-action-lawsuit-mrvi.html \u00a0 … <\/p>\n

Continue reading “MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-823657","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , March 10, 2025 \/PRNewswire\/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), have until May 5, 2025 to seek appointment as lead plaintiff of the Maravai class action lawsuit.\u00a0 Captioned Nelson v. Maravai LifeSciences Holdings, Inc., No. 25-cv-00499 (S.D. Cal.), the Maravai class action lawsuit charges Maravai as well as certain of Maravai’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Maravai class action lawsuit, please provide your information here: https:\/\/www.rgrdlaw.com\/cases-maravai-lifesciences-holdings-inc-class-action-lawsuit-mrvi.html \u00a0 … Continue reading "MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-10T13:23:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit\",\"datePublished\":\"2025-03-10T13:23:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/\"},\"wordCount\":729,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/\",\"name\":\"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"datePublished\":\"2025-03-10T13:23:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2542335\\\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , March 10, 2025 \/PRNewswire\/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), have until May 5, 2025 to seek appointment as lead plaintiff of the Maravai class action lawsuit.\u00a0 Captioned Nelson v. Maravai LifeSciences Holdings, Inc., No. 25-cv-00499 (S.D. Cal.), the Maravai class action lawsuit charges Maravai as well as certain of Maravai’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Maravai class action lawsuit, please provide your information here: https:\/\/www.rgrdlaw.com\/cases-maravai-lifesciences-holdings-inc-class-action-lawsuit-mrvi.html \u00a0 … Continue reading \"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-10T13:23:18+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit","datePublished":"2025-03-10T13:23:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/"},"wordCount":729,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","name":"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","datePublished":"2025-03-10T13:23:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2542335\/robbins_geller_rudman_and_dowd_llp_logo_v2_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mrvi-investor-deadline-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MRVI INVESTOR DEADLINE: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=823657"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823657\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=823657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=823657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=823657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}